About atbtherapeutics

At atbtherapeutics, we are pioneering a new era in targeted therapies by developing next-generation Antibody-Drug Conjugates (ADCs) to revolutionize cancer treatment. Combining cutting-edge biotechnology with a deep commitment to improving patient outcomes, we are on a mission to deliver safer, more effective, and highly selective treatments to address unmet medical needs.

Our proprietary atbodies™ platform enables the design and production of unique biological molecules that combine the specificity of antibodies with potent payload delivery, achieving unprecedented precision in targeting cancer cells while sparing healthy tissues. With innovation at our core and a world-class team driving progress, atbtherapeutics is transforming therapeutic possibilities into tangible solutions for patients worldwide.